尼达尼布联合培美曲塞/顺铂治疗恶性胸膜间皮瘤的II期随机对照研究
LUME-Meso是一项II/III期随机双盲试验,评估尼达尼布联合培美曲塞/顺铂一线治疗不可切除非肉瘤样恶性胸膜间皮瘤的疗效与安全性。II期部分纳入87例患者,尼达尼布组中位无进展生存期显著优于安慰剂组(HR 0.56,P=0.017),上皮样组织学亚组获益明显,不良反应可管理。
要点
- 尼达尼布联合化疗较安慰剂显著改善无进展生存期(HR 0.56,95%CI 0.34–0.91,P=0.017)。
- 上皮样组织学亚组中位总生存期延长5.4个月(20.6 vs 15.2个月,HR 0.70,P=0.197)。
- 中性粒细胞减少是最常见≥3级不良事件(尼达尼布组43.2% vs 安慰剂组12.2%)。
核心结论
- 尼达尼布联合培美曲塞/顺铂一线治疗不可切除非肉瘤样恶性胸膜间皮瘤可改善无进展生存期,不良反应可管理,上皮样组织学患者临床获益明显。
研究设计与样本
- LUME-Meso为II/III期随机双盲安慰剂对照试验,II期部分纳入87例未接受化疗的不可切除非肉瘤样恶性胸膜间皮瘤患者(ECOG PS 0–1),按组织学(上皮样或双相型)分层,1:1随机分配至最多6周期培美曲塞+顺铂联合尼达尼布(200 mg每日两次)或安慰剂,后续尼达尼布+安慰剂单药维持直至进展。
- 主要终点为无进展生存期。
主要发现
- 中位培美曲塞+顺铂周期数为6;尼达尼布中位治疗持续时间7.8个月,安慰剂组5.3个月。
- 主要分析无进展生存期 favoring 尼达尼布(HR 0.56,95%CI 0.34–0.91,P=0.017),更新分析确认(HR 0.54,95%CI 0.33–0.87,P=0.010)。
- 总生存期趋势 favoring 尼达尼布(HR 0.77,95%CI 0.46–1.29,P=0.319)。
- 上皮样组织学亚组中位总生存期尼达尼布组20.6个月 vs 安慰剂组15.2个月(HR 0.70,95%CI 0.40–1.21,P=0.197),中位无进展生存期尼达尼布组9.7个月 vs 安慰剂组5.7个月(HR 0.49,95%CI 0.30–0.82,P=0.006)。
- 中性粒细胞减少为最常见≥3级不良事件(尼达尼布组43.2% vs 安慰剂组12.2%);发热性中性粒细胞减少发生率低(尼达尼布组4.5% vs 安慰剂组0%);导致停药的不良事件尼达尼布组6.8% vs 安慰剂组17.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM). Phase II results are reported here. Patients and Methods Chemotherapy-naïve patients with unresectable, nonsarcomatoid MPM (Eastern Cooperative Oncology Group performance status 0 to 1), stratified by histology (epithelioid or biphasic), were randomly assigned in a 1:1 ratio to up to six cycles of pemetrexed and cisplatin plus nintedanib (200 mg twice daily) or placebo followed by nintedanib plus placebo monotherapy until progression. The primary end point was progression-free survival (PFS). Results Eighty-seven patients were randomly assigned. The median number of pemetrexed and cisplatin cycles was six; the median treatment duration for nintedanib was 7.8 months and 5.3 months for placebo. Primary PFS favored nintedanib (hazard ratio [HR], 0.56; 95% CI, 0.34 to 0.91; P = .017), which was confirmed in updated PFS analyses (HR, 0.54; 95% CI, 0.33 to 0.87; P = .010). A trend toward improved overall survival also favored nintedanib (HR, 0.77; 95% CI, 0.46 to 1.29; P = .319). Benefit was evident in epithelioid histology, with a median overall survival gain of 5.4 months (HR, 0.70; 95% CI, 0.40 to 1.21; P = .197; median [nintedanib v placebo], 20.6 months v 15.2 months) and median PFS gain of 4.0 months (HR, 0.49; 95% CI, 0.30 to 0.82; P = .006; median [nintedanib v placebo], 9.7 v 5.7 months). Neutropenia was the most frequent grade ≥ 3 adverse event (AE; nintedanib 43.2% v placebo 12.2%); rates of febrile neutropenia were low (4.5% in nintedanib group v 0% in placebo group). AEs leading to discontinuation were reported in 6.8% of those receiving nintedanib versus 17.1% of those in the placebo group. Conclusion Addition of nintedanib to pemetrexed plus cisplatin resulted in PFS improvement. AEs were manageable. The clinical benefit was evident in patients with epithelioid histology. The confirmatory phase III part of the study is ongoing.
引用
- Grosso F, Steele N, Novello S, et al. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. J Clin Oncol. 2017. PMID: 28892431. doi:10.1200/JCO.2017.72.9012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。